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HNPCC is an autosomal inherited cancer syndrome characterized by germinal and somatic mutations of
DNA mismatch repair (MMR) genes. The inherited mutation in one allele together with an acquired
defect in the other allele of an MMR gene leads to accelerate tumor progression.
In this study we analyzed a cohort of 11 subjects belonging to four Sicilian families with HNPCC
suspected by molecular analysis of coding regions of hMSH2 (NC_000002) and hMLH1 (NC_000003)
genes.
Molecular analysis has detected the presence of two mutations in gene MSH2 and one mutation in
MHL1 gene. In addition, we found a novel mutation consisting in a G deletion at 914 codon of the exon 16
in the MSH2 gene. This deletion leads to a stop codon due to a frame-shift, resulting in a truncated
protein.
We extended genetic analysis to the other family members and the same mutation was detected in
three sisters and in one of the two healthy daughters.
This mutation is correlated with clinical ﬁndings revealed in genealogic tree and it represents a novel
mutation responsible of HNPCC.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Colorectal cancer (CRC) is one of the most common and pre-
ventable forms of cancers worldwide. Its incidence varies among, Organ Transplantation and






by Elsevier Ltd. All rights reserveddifferent populations with the highest incidence reported from
Western and industrialized countries.
Several genetic and environmental factors contribute to the
development of cancer and it is estimated that up to 35% of all
colorectal cancers are caused by a genetic predisposition [1e4].
Hereditary non-polyposis colorectal cancer (HNPCC) is the most
common inherited syndrome predisposing to colorectal cancer
(CRC), accounting for approximately 5e10% of all cases CRC [5,6].
Approximately 10%e15% of patients with colorectal cancer have
a family history of colorectal cancer, and 5% of patients have early-
onset (45 years) colorectal cancer. In the etiology of colorectal
cancer in these cases, several genetic factors are likely to play a
partial role, as do dietary and other environmental inﬂuences..
A. Cavallaro et al. / International Journal of Surgery 12 (2014) S120eS124 S121Lynch syndrome patients are also at risk of developing extrac-
olonic malignancies in a variety of organs such as uterus, small
bowel, stomach, ovary, bladder, pancreas, urinary tract and the
brain cancer. The syndrome is characterized by early onset
epithelial cancers, proximal predominance of colorectal cancer,
excess of synchronous and metachronous tumors.
HNPCC is an autosomal dominant condition caused by a defect
in one of the mismatch repair (MMR) genes [5]. Germline muta-
tions of genes involved in post-replicative DNA mismatch repair
(MMR), in particular hMLH1, hMSH2, hPMS1, hPMS2, hMSH3, and
hMSH6, are thought to be responsible for HNPCC as they cose-
gregate with the HNPCC phenotype [7,8].
However, the majority of mutation (90%) have been identiﬁed in
hMLH1 and hMSH2 genes and only 10% in hMSH6 gene [9].
Most of them are small insertions/deletions leading to a frame-
shift, resulting truncated protein with loss of function. About
10e30% of mutations responsible for HNPCC are large genomic
rearrangements scattered throughout the coding regions of the two
genes.
Due to the genetic heterogeneity and clinical variability among
HNPCC families, the identiﬁcation of germline mutations becomes
laborious.
An inherited defect in one of these genes, combined with an
acquired defect in the wild-type allele, compromise MMR and thus
promote genetic instability and tumorigenesis. Conversely, non-
truncating mutations can either be neutral variations or lead to a
highly increased cancer risk and LS.
Usually, clinical characteristics described in Amsterdam I, II
criteria are used to discriminate an HNPCC from a sporadic colon-
rectal cancer. The use of these criteria does not offer an optimal
screening strategy to predict the subsequent detection of a patho-
genic germline mutation, because a largely variability (i.e. age
onset, tumor spectrum) is usually present within family members
and subjects carrying the same mutation. Part of the phenotypic
variation between carriers of similar mutations may be explained
by different life styles or the existence of modifying genes.
In addition, the Amsterdam criteria tend to exclude HNPCC
families with only extracolonic tumors and patients with a limited
family history.
Recently, molecular investigations of mutations that lead to loss
of function in the mismatch repair genes have been used to
correctly identify patients with HNPCC.
The identiﬁcation of a germline mutation in the proband is
crucial to extend the molecular analysis of family members and
offered a surveillance program that will hopefully reduce cancer
mortality.
Mutations in hMSH2 (NC_000002) and hMLH1 (NC_000003)
genes were analyzed in patients from Caucasian families suspected
HNPCC by clinical examination.
2. Materials and methods
All patients recruited are HNPCC suspected. We enrolled four
subjects. The purpose of the study was explained, and informed
consent was obtained from all participating patients. Personal and
familial cancer history was collected, including site and type of
cancer. Peripheral blood was obtained from the probands and
family members.
Screening was completed in 4 families. Testing was initially
carried out on DNA from an affected family member and upon
detection of described mutations and a novel inactivating muta-
tion, the rest of the family members were directly tested for these
mutations.
Total genomic DNA was extracted from peripheral blood lym-
phocytes using standard method phenol-chloroform, and storedat20 C. All coding exons and the introneexon boundaries of both
MSH2 (16 exon) and MLH1 (19 exon) genes were ampliﬁed from
genomic DNA by polymerase chain reaction (PCR) method, using
speciﬁc primers for each region. Primers were selected using the
PRIMER Program. Ampliﬁcation products were run by 1% agarose
gel electrophoresis stained with SYBR Safe DNA gel stain. Genomic
DNA was used to amplify via polymerase chain reaction (PCR) the
regions of both MLH1 and MSH2 genes. PCR products were puriﬁed
with Microcon Centrifugal ﬁlter devices (Millipore) and sequenced
by an automated ABI PRISM 310 sequencing apparatus (Applied
Biosystem, Foster City, CA). Sequencing reactions were carried out
by the ABI PRISM BigDye Terminator Cycle Sequencing Ready Re-




The proband (III:1) is a 44 years-old woman with a right colon
cancer pT3N0 G2. Hermother (II:1) was suffering from colon cancer
and uterus cancer, but she died of colon cancer. Her father (II:2)
died due to emphysema. The grandmother (I:2) had a breast can-
cer; one of the four sisters (III:5) had both uterus (45 y) and colo-
rectal cancer (53 y), two of the others three sisters had only an
endometrial cancer (III:6 53 y) (III:8 44 ys, with metastases at
onset), while all the three brothers exhibit no malignancy. The
proband's two daughters (IV:1; IV:2), 22 and 24 years old, were in
good health, the older with the mutation, the younger no. Four
years later, 48 years old, the proband developed an endometrial
adenocarcinoma pT1b (IB FIGO)Nx (Fig. 1).
3.2. Family 2
The proband (II:1) is a 51 years-old woman with a right colon
cancer pT3pN2 (4/24 lgh) G2. The father (I:1) died of a stroke. The
mother (I:2) died of a malignant ovarian tumor. The proband has
three sisters, one of which had died because of colon cancer at the
age of 34 years (II:2), one had no mutations, the about the third we
do not have news. One of the two brothers had no mutation, the
other was not studied.
The four proband's sons were submitted to molecular analysis;
two sons developed colon cancer (III:1 with a right colon cancer
T3N0 G2 at the age of 35 y; III:2 Left colon cancer in situ pT1s G2 at
the age of 38 y). The other two sons were in good health. Two years
after the colorectal neoplasia, the proband had a low differentiated
endometroid adenocarcinoma with a wide squamous metaplasia
PT2N0G3, FIGO II. Six months after she had a low differentiated
endometrioid lung metastases (Fig. 2).
3.3. Family 3
The proband (II:3) is a 47 years-old man dx colon cancer
affected. His mother (I:1) stomach adenocarcinoma affected. His
father (I:2) affected by HHC. The proband has two brothers and two
sisters. The sisters were in good health. The brothers are affected by
colon adenocarcinoma (II:1) and breast cancer (II:2), respectively.
The proband has two daughters, 20 and 24 years old (Fig. 3).
3.4. Family 4
The proband is a 28 years-old woman sx colon cancer affected.
The grandfather is dead because of the colon cancer. Her father and
her mother are 58 and 60 years-old respectively. The proband has
one brother of 19 years-old and he is in good health.
Fig. 1. Family 1 tree.
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All coding exons and the introneexon boundaries of MSH2 gene
(16 exons) were analyzed in the proband of family 1(III:1), by
molecular analysis and direct sequencing.
We found a novel mutation consisting in a G deletion belonging
to the 914 codon of the exon 16 in the MSH2 gene. This deletion
leads to a premature stop codon (position 916), causing a frame-
shift and the formation of a truncated protein (Fig. 4).
The combination of the mutation with loss of the wild-type
allele compromises MMR genes, thus it promotes genetic insta-
bility and tumor formation. The sequencing analysis of the other
exons has not revealed any changes.Fig. 2. Family 2 tree.We extended genetic analysis to the other family members and
we found the same mutation in three out of the four proband's
sisters (III:5 colon and uterus cancer affected; III:6 uterus cancer
affected; III:8 metastatic uterus cancer) and in one proband's
daughter (IV:1 healthy). The rest of the family members were un-
available for analysis.
Molecular analysis and direct sequencing of MSH2 gene in the
proband of family 2 (II:1) has detected the presence of themutation
previously described by Miyaki et al., 1995 [10]. This mutation
consists in an A insertion, in the region surrounding the 227 and the
228 codons of exon 4, which results in frame-shift and creates a
stop codon.We extended the analysis to fourmembers of proband's
family because the others were unavailable. The mutation was also
identiﬁed in two proband's sons (III:1 colon ca; III:2 colon ca). In
addition, the test didn't showanymutation in proband's sister (II:3)
and brother (II:5).
In the proband of family 3 (II:3) we didn't found anymutation in
the MSH2 gene. His relatives didn't want to take part in the genetic
test.
The genetic analysis of proband’s family 4 has shown a G>A
substitution, in heterozygous condition, in the codon 322
(GGC/ GAC), that led to substitution of a glycine with an aspar-
agine (G322D) described by Olilla S. et al 2008 [11].Fig. 3. Family 3 tree.
Fig. 4. Deletion G at the 914 codon of the exon 16 in the MSH2 gene. Deletion G leads to a stop codon (position 916) resulting in a truncated protein.
A. Cavallaro et al. / International Journal of Surgery 12 (2014) S120eS124 S1233.6. MLH1 gene
Molecular analysis by direct sequencing of the 19 coding exons
and the introneexon boundaries of the MLH1 gene didn't show any
mutation in the proband (III:1) of the family 1 and in the proband
(II:1) of the family 2. These results did not lead to extend the ge-
netic test to the others family members.
In the proband (II:3) of the family 3 the molecular analysis has
shown an A>G substitution (ATC/GTC), in heterozygous condi-
tion, that led to a substitution of an isoleucine with a valine at
codon 219 (I219V), reported by Tomlinson et al., 1997 [12] as a
polymorphism with a frequency of 13%.
The same polymorphism in homozygous conditionwas found in
the proband of family 4.4. Discussion and conclusion
We carried out molecular analysis of the hMSH2 and hMLH1
genes implicated in the HNPCC syndrome in a cohort of four
Caucasian families with suspected HNPCC.
The most of mutations identiﬁed in the MSH2 and MLH1 genes
are small insertions/deletions leading to frame-shifts and truncated
protein products [13].
In MLH1 and MSH2 genes we identiﬁed four mutations, one of
which is in the MLH1 gene and three are in the MSH2 gene. In the
MLH1 gene are present mainly missense mutations, while in the
MSH2 gene are the most frequent alterations that lead to truncated
proteins [14].
About the variant of MLH1 gene present in the proband of
families 3 and 4 it is not possible to determine whether it is a novel
mutation or a mutation inherited from a parent, because the family
did not take part in the screening.
In this study we identiﬁed a novel mutation that consists of a G
deletion at 914 codon in the MSH2 gene, this deletion lead to a stop
codon resulting in a truncated protein. To deﬁne the pathogenicity
of the novel mutation, we followed its segregation with the disease
phenotype in the majority of relatives conﬁrming the pathogenic
nature of the mutation.
Mutation G322D found in the MSH2 gene leads to variable and
contradictory interpretations of its pathogenicity, in fact it has been
described both as pathogenic and non-pathogenic in literature and
databases. The majority of the published data discusses MSH2
G322D as a neutral polymorphism, it has also been hypothesized to
be a low penetrance allele [11].
In contrast with these interpretations, a recently published
population-based study raises a possibility of G322D being instead
of pathogenic a protective allele further complicating its classiﬁ-
cation [15].
Many mutations have been identiﬁed in MMR genes, this
genotypic diversity is reﬂected in the phenotypic characteristicvariety of the syndrome. The phenotypic diversity may indicate
that other factors can inﬂuence the penetrance of the molecular
defect.
Cliniciansmake use of the Amsterdam criteria that were initially
proposed to select kindreds suitable for the localization and the
identiﬁcation of genes involved in the syndrome [16].
However, several reports have shown that the clinical of HNPCC
based on the Amsterdam criteria is more stringent than a deﬁnition
based on the involvement of MMR genes. The Amsterdam criteria
include only the age of onset and the number of CRCs within a
family. Considering the cost of screening methodologies, it appears
essential to identify pathological and clinical factors that predict
the outcome of genetic analysis. Based upon our results and in
accordancewith a report byWijnen et al., 1998 [17], the presence of
multiple tumors in a single member of a family and the presence of
endometrial cancer in a family should be included among the
guidelines for referring patients for genetic testing.
In conclusion, genetic analysis allows to identify carriers of
mutation in pre-symptomatic phase and this is of crucial impor-
tance for subjects belonging to families at risk of colon cancer.
Asymptomatic subjects in which the molecular diagnosis indicates
the presence of mutations are directed to a closer clinical moni-
toring and they are inserted into a screening program in order to
detect early the presence of polyps before they transform into
cancer.
Increased knowledge about inherited susceptibility for cancer
and the identiﬁcation of genes associated with cancer risk has
increased the need for individuals with training in genetics to work
closely with oncology professionals in the familial cancer arena
[18e24]. Genetic counselors can provide a variety of useful ser-
vices: They may function as clinical coordinators of a family cancer
risk counseling (FCRC) program and serve as study coordinators on
research teams. In the oncology practice setting, genetic counselors
who are trained to do cancer risk counseling can help ascertain and
evaluate familial clusters of cancers. In the context of FCRC, the
genetic counselor can educate family members about risk factors
for cancer and the signiﬁcance of a positive family history, assess
psychosocial functioning and provide psychosocial support and
referrals. Genetic susceptibility testing should be offered only with
appropriate genetic counseling.Ethical approval
This is a retrospective study based only on the analyses of
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